Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports ...

Travere Therapeutics (TVTX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The government’s decision to reject the two names recommended by Amicus Curiae Adv Nigel de Costa Frias on the Noise Monitori ...

Advocate Mitha Sudhindran, appointed as Amicus Curiae by the special Bench hearing matters related to the Justice Hema ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Amicus (FOLD – Research Report), with a price target of $20.00.

Ivim Health raises concern over US FDA’s arbitrary critical deadline comes; submits Amicus brief to fighting patient access to GLP-1 medications: Columbus, Ohio Thursday, Februa ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...